These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
23. Diagnosis and treatment of irritable bowel syndrome. Dalton CB; Drossman DA Am Fam Physician; 1997 Feb; 55(3):875-80, 883-5. PubMed ID: 9048508 [TBL] [Abstract][Full Text] [Related]
24. [Irritable bowel syndrome. Survey of definitions, differential diagnosis and pathogenesis]. Bodemar G; Ragnarsson G Lakartidningen; 2001 Feb; 98(7):666-71. PubMed ID: 11475255 [TBL] [Abstract][Full Text] [Related]
25. [Therapeutic strategy in the irritable bowel syndrome]. Thompson WG Gastroenterol Clin Biol; 1990; 14(5 ( Pt 2)):74C-80C. PubMed ID: 2210190 [TBL] [Abstract][Full Text] [Related]
26. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555 [TBL] [Abstract][Full Text] [Related]
27. New developments in the treatment of irritable bowel syndrome. De Schryver AM; Samsom M Scand J Gastroenterol Suppl; 2000; (232):38-42. PubMed ID: 11232489 [TBL] [Abstract][Full Text] [Related]
29. Treatment of irritable bowel syndrome. Rock L; Nasrallah SM Compr Ther; 1984 Dec; 10(12):18-23. PubMed ID: 6097397 [No Abstract] [Full Text] [Related]
30. [Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome]. Wittmann T; Fehér A; Rosztóczy A; Jánosi J Orv Hetil; 1999 Feb; 140(9):469-73. PubMed ID: 10204402 [TBL] [Abstract][Full Text] [Related]
31. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Shah SB; Hanauer SB Rev Gastroenterol Disord; 2007; 7 Suppl 3():S3-10. PubMed ID: 18192964 [TBL] [Abstract][Full Text] [Related]
32. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764 [TBL] [Abstract][Full Text] [Related]
33. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Pimentel M; Chow EJ; Lin HC Am J Gastroenterol; 2000 Dec; 95(12):3503-6. PubMed ID: 11151884 [TBL] [Abstract][Full Text] [Related]
34. [Epidemiology of intestinal functional disorders in an apparently healthy population]. Bommelaer G; Rouch M; Dapoigny M; Pais D; Loisy P; Gualino M; Tournut R Gastroenterol Clin Biol; 1986 Jan; 10(1):7-12. PubMed ID: 3956914 [TBL] [Abstract][Full Text] [Related]
35. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693 [TBL] [Abstract][Full Text] [Related]
36. Management of irritable bowel syndrome. Viera AJ; Hoag S; Shaughnessy J Am Fam Physician; 2002 Nov; 66(10):1867-74. PubMed ID: 12469960 [TBL] [Abstract][Full Text] [Related]
37. Dyspepsia, irritable bowel syndrome, and constipation: review and what's new. Camilleri M Rev Gastroenterol Disord; 2001; 1(1):2-17. PubMed ID: 12120117 [TBL] [Abstract][Full Text] [Related]
38. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Cann PA; Rovati LC; Smart HL; Spiller RC; Whorwell PJ Ann N Y Acad Sci; 1994 Mar; 713():449-50. PubMed ID: 8185213 [No Abstract] [Full Text] [Related]